Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC). Update February 2021

Grössmann, N. (2021): Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC). Update February 2021. Oncology Fact Sheet Nr. 26.

[thumbnail of Oncology Fact Sheet Nr.26_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
75kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WI Digestive system > WI 250 Oesophagus
Language:	English
Series Name:	Oncology Fact Sheet Nr. 26
Deposited on:	18 Nov 2020 11:48
Last Modified:	01 Feb 2021 18:34

Repository Staff Only: item control page